key: cord-0298220-lns65ekb
authors: de la Court, J. R.; Coenen, S.; Buis, D. T. P.; Meijboom, L. J.; Schade, R. P.; Visser, C. E.; van Hest, R. M.; Kuijvenhoven, M.; Prins, J. M.; Nijman, S. F. M.; Sieswerda, E.; Sigaloff, K. C. E.
title: Low frequency of community-acquired bacterial co-infection in patients hospitalized for COVID-19 based on clinical, radiological and microbiological criteria; a retrospective cohort study.
date: 2021-07-02
journal: nan
DOI: 10.1101/2021.06.23.21259020
sha: 38a3021a7a7d5fdf97d70dc828e3428617f34c12
doc_id: 298220
cord_uid: lns65ekb

Background To define the frequency of respiratory community-acquired bacterial co-infection in patients with coronavirus disease 2019 (COVID-19) based on a complete clinical assessment, including prior antibiotic use, clinical characteristics, inflammatory markers, chest computed tomography (CT) results and microbiological test results. Methods This study was conducted within a cohort of prospectively included patients admitted for COVID-19 in our tertiary medical centres between 1-3-2020 and 1-6-2020. A multidisciplinary study team developed a diagnostic protocol to retrospectively categorize patients as unlikely, possible or probable bacterial co-infection based on clinical, radiological and microbiological parameters in the first 72 hours of admission. Within the three categories, we summarized patient characteristics and antibiotic consumption. Results Among 281 included COVID-19 patients, bacterial co-infection was classified as unlikely in 233 patients (82.9%), possible in 35 patients (12.4%) and probable in 3 patients (1.1%). Ten patients (3.6%) could not be classified due to inconclusive data. Within 72 hours of hospital admission, 81% of the total study population and 78% of patients classified as unlikely bacterial co-infection received antibiotics. Conclusions COVID-19 patients are unlikely to have a respiratory community-acquired bacterial co-infection. Prospective studies should define the safety of restrictive antibiotic use in COVID-19 patients.

Antibiotics are frequently prescribed to COVID-19 patients upon admission out of fear of a bacterial All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint co-infection (1) (2) (3) . The decision to administer antibiotics is likely influenced by the frequent presence of consolidations on chest computed tomography (CT), high inflammatory markers and frequent bacterial co-infections in patients with influenza (4, 5) . Recent studies suggest bacterial co-infection is present in less than 10% of COVID-19 patients (2, (6) (7) (8) . They seem mostly hospital-acquired.

Community-acquired bacterial co-infections occur in 1.2 -3.5% of patients (6, 7, 9, 10) . However, in these studies bacterial co-infection was diagnosed based on microbiological test results only. This could lead to underestimation, since microbiological tests are not obtained in all patients and are negative for the majority of patients with community-acquired pneumonia (CAP) (11) . Conversely, positive microbiological test results of respiratory tract samples may represent bacterial colonization.

To date, one study has attempted to assess the prevalence of bacterial CAP in COVID-19 patients, based on clinical, radiological and microbiological criteria (12) . The threshold for diagnosing possible bacterial CAP in this study was low, i.e. the presence of one clinical criterion sufficed (such as fever and elevated white blood cell count). The authors reported that in 49% of patients bacterial coinfection was either possible, probable or proven. Given the overlap between symptoms of COVID-19 and bacterial CAP, this percentage may be an overestimation. In order to more reliably identify patients in whom a bacterial CAP is likely, complete patient evaluation of initial presentation and clinical course is essential. We therefore defined the frequency of community-acquired respiratory bacterial co-infection (further abbreviated to co-infection) in COVID-19 patients, based on a complete clinical assessment, including prior antibiotic use, clinical characteristics, inflammatory markers, chest CT and microbiological test results.

We performed a retrospective analysis within the CovidPredict Clinical Course Cohort, performed at the two centers of Amsterdam UMC, a tertiary care hospital (13) . Data for this cohort was prospectively gathered from electronic health records according to the case report form (CRF) designed by the World Health Organization (WHO, (14)). This study was approved by the Medical Ethics Committee VUmc (Amsterdam, the Netherlands); All necessary patient consent has been obtained and archived.

The cohort includes all adults admitted to Amsterdam UMC with positive SARS-CoV-2 PCR of a respiratory tract sample, or chest CT typical for COVID-19 (COVID-19 Reporting and Data System (CO-RADS) ≥ 4 (15)) since February 2020 (13, 16) . Collected data comprises demographics, comorbidities, medication, laboratory tests, microbiological test and chest CT results, treatment and clinical All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint outcomes. Clinical outcome, defined as mortality, admission to ICU or general ward or discharged to their home or rehabilitation centre, is ascertained for this study at 3 weeks after hospital admission by chart review. For the current study, we included patients admitted directly to the Amsterdam UMC from 27-2-2020 to 1-6-2020. This inclusion period represents the first 'wave' of COVID-19 in The Netherlands. Exclusion criteria were: nosocomial COVID-19 infection, re-admission or transfer from another hospital or health care institution and no chest CT within 72 hours of admission.

Clinical characteristics included were prior antibiotic use, symptoms at admission (cough, chest pain, dyspnea and confusion), CURB-65 score and inflammatory parameters, i.e. C-reactive protein (CRP) and procalcitonin (PCT). We assessed the clinical course within 72 hours of admission, including admission to ICU, clinical recovery or deterioration, in-or decrease of inflammatory markers in the presence or absence of antibiotics and clinical state in case of hospital discharge. assessments were made by two physicians. Any discrepancies in categorization were resolved in a All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint total of four expert panel meetings.

We performed a descriptive analysis of clinical and laboratory tests. Continuous variables were summarized by mean and standard deviation or by medians and interquartile range (IQR).

Categorical variables were presented by counts and percentages. Frequency data were summarized as proportions.

We summarized proportions of patients receiving antibiotics and described the median duration of antibiotic therapy. Overall in-hospital antibiotic use was measured as days of therapy (DOTs), standardized per 100 patient days and per 100 admissions. Patient days were calculated by subtracting day of admission from day of discharge.

Data analysis was performed using R Statistical Software (version 3.6.1; R Foundation for Statistical Computing, Vienna, Austria). Data visualization was performed using TIBCO® Spotfire®.

During the study period, 384 COVID-19 patients were included in the CovidPredict database. We excluded 70 patients who were re-admitted, transferred from another hospital or had nosocomial COVID-19 and 33 patients without chest CT within 72 hours of hospital admission (Figure 1 ). Mean age was 61 years, median CRP 86 mg/L (n=270), median PCT 0.14 ng/mL (n=86, table 1). In 43 (15.3%) patients antibiotics were prescribed prior to admission. Three weeks after hospital admission 214 (76%) patients were discharged to their home, a nursing home or rehabilitation unit, 17 (6.0%) were still admitted to the ICU, 15 (5.3%) were still admitted to the general ward and 35 (12%) patients had died or were transferred to palliative care (data not shown).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint

In 10 patients categorization was not possible due to inconclusive data. 1 No respiratory symptoms and no altered mental status. 2 No large, lobar or unilateral consolidations. 3 Culture, PCR or urinary antigen tests. CT: Computed tomography scan; CRP: C-reactive protein 42.0 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint Numbers are n (%) unless otherwise indicated. In 10 patients classification (as probable, possible and unlikely co-infection) was not possible due to inconclusive data. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. and unlikely in 233 patients (82.9%, Figure 1 and Table 1 ). In 10 (3.6%) patients categorization was not possible due to inconclusive data, i.e. no follow-up inflammatory parameters were available All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint enabling evaluation of the effect of administering or withholding antibiotics. In the 233 patients classified as unlikely co-infection, 33 (14%) had no respiratory symptoms and no altered mental status. In 124 (53%) patients CRP was below 100 mg/L, chest CT was not consistent with co-infection and microbiological test results were negative. In 76 (33%) patients, co-infection was considered unlikely after expert panel review. Of these, in 32 (42%) patients no consolidations were described on chest CT. In 42 (55%) patients, consolidations were present but not consistent with co-infection, and there were no clinical or microbiological findings to support co-infection. Two 

Antibiotics were initiated in 228 (81%) patients within 72 hours of admission ( Table 2) . Among patients classified as unlikely co-infection, 182 (78%) received antibiotics for a median duration of 4 days (IQR 2-5). In 109 (47%) patients antibiotic treatment was continued beyond 3 days. Among patients classified as possible or probable co-infection, 36 (95%) received antibiotics for a median All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint duration of 5 days (IQR 4-6). Ceftriaxone was the most frequent administered systemic antibiotic with a total of 774 DOT, resulting in 275 DOT ceftriaxone/100 admissions (Figure 3) . According to the Dutch national guideline on CAP (17) , based on the CURB-65 score ceftriaxone could be replaced by amoxicillin in 143/167 (85.6%) patients. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. Other monotherapy*** 6 (2.1) 6 (2.6) 0 (0)

Numbers are n (%) *Including patients in whom both amoxicillin + ceftriaxone was given.

** Other combination therapy: a combination of beta-lactam antibiotics, combination of beta-lactam antibiotic with macrolide/quinolone/glycopeptide/cotrimoxazole/metronidazole or combinations of three different antibiotic classes.

***Other monotherapy: other beta-lactam antibiotics (e.g. flucloxacillin or ceftazidime) or any of the other antibiotic classes (e.g. nitrofurantoin, cotrimoxazole).

In our study, 83% of COVID-19 patients had no co-infection based on complete clinical assessment, including prior antibiotic use, clinical characteristics, inflammatory markers, chest CT results and microbiological test results. Using a multidisciplinary approach, we considered co-infection probable in 1.1% and possible in 12.4%. Despite the low frequency of co-infection, antibiotic treatment was initiated in 81% of patients, and ceftriaxone was prescribed most frequently. Our study underpins recent preliminary recommendations for restrictive use of antibacterial drugs in patients with proven or a high likelihood of COVID-19 (18) .

Our reported low probably of co-infection is in line with previous study results on co-infections based on microbiological test results only (6, 7, 9, 10) . By means of this study, we addressed the limitation of previous reports, i.e. co-infection is not confirmed or ruled out by microbiological test results alone (19) . Indeed, we found that only 11/38 (29%) patients classified as possible or probable co-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. One recent study by Karaba et al. also included clinical and radiological criteria to assess the frequency of co-infection and concluded that co-infection was proven in 0.3%, probable in 1.1% and possible in 48% of patients (12) . In contrast to our study, the authors found co-infection unlikely in only 51% of patients. This large difference could be explained by the different criteria used for coinfection. Karaba has a higher sensitivity and specificity for bacterial CAP compared to chest radiograph (20) .

Chest CT was an important factor in our categorization. No previous studies defined the role of chest CT for co-infections in COVID-19 patients. In patients with compatible clinical characteristics, we considered large, lobar or unilateral consolidations consistent with co-infection, in accordance with international guidelines (21) . Chest CT was consistent with co-infection in 9/38 (24%) patients classified as probable or possible co-infection. However, the majority of chest CTs showed typical findings for COVID-19, i.e. ground glass opacities, characteristically with a peripheral and subpleural distribution as described in the CO-RADS scale (15) . Such opacities may be mixed with areas of focal consolidation, of which linear consolidations and reversed halo sign suggest organizing pneumonia (22) (23) (24) .

Strengths of this study include the structured classification of patients, using a predefined, standardized and reproducible clinical evaluation. We reviewed all chest CTs, microbiology data and clinical parameters for each patient. These clinical parameters were prospectively collected and had little missing data. Independent assessments were made by two physicians and discrepancies were resolved by the expert panel. Patients were included prospectively, reducing the risk of selection bias.

Our study has limitations that should be acknowledged. First, our categorization of patients was retrospective in nature which may have biased our categorization. However, we standardized the criteria we used for the final classification to minimize this bias. Second, complete diagnostic work-up was not available in all patients, for example, procalcitonin was only measured in 86 patients. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint However, overall there was little missing data as clinical parameters were prospectively collected.

Third, atypical bacterial pneumonia may be difficult to distinguish from COVID-19 on chest CT (22) (23) (24) (25) (26) . Therefore, the frequency of atypical bacterial pneumonia may have been underestimated.

However, as only 1 (1.7%) of the 60 tests for atypical pathogens was positive, this risk of bias is deemed low.

Fourth, use of antibiotics prior to admission may have confounded our results. Fifteen percent of patients reported antibiotic use prior to admission, which could have led to underestimation of the frequency of co-infection as prior antibiotic use can lead to false-negative microbiological test results.

Lastly, we studied COVID-19 patients in the first 'wave' when patients did not receive corticosteroids yet. The current standard use of corticosteroids for the treatment of COVID-19 may impact the frequency of bacterial infections in this population (27). However, as COVID-19 patients currently only receive corticosteroids when hospitalized, this will most likely not have a large effect on the prevalence of co-infection.

Our study suggests that implementation of the recent recommendations for restrictive antibacterial therapy in COVID-19 patients has the potential to greatly reduce antibiotics use (18) . Although the effect of the pandemic on antimicrobial resistance development is yet unclear, the unnecessary use of antibiotics should be avoided. Up to now, the majority of patients have received broad-spectrum antibiotics which, in combination with prolonged hospital admission, has exposed them to the risk of health-care-associated infections and transmission of (multidrug-)resistant organisms (28, 29). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint

How covid-19 is accelerating the threat of antimicrobial resistance

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

A call for antimicrobial stewardship in patients with COVID-19: a nationwide cohort study in Korea

Bacterial and viral co-infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013-14

The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses

Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a retrospective cohort study

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands

Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study

Antibiotic treatment strategies for community-acquired pneumonia in adults

Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study

The COVID-19 Core Case Report Form

CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation

Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT)

The Dutch Working Party on Antibiotic Policy (SWAB) recommendations for antibacterial therapy in adults with COVID-19

Limited usefulness of initial blood cultures in community acquired pneumonia

Computed tomography scan contribution to the diagnosis of community-acquired pneumonia

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the

Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

COVID-19 pneumonia: A review of typical CT findings and differential diagnosis

Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients

Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprintWe would like to thank the CovidPredict consortium (www.covidpredict.org), specifically Joost Wiersinga and Michiel Schinkel, for their efforts in providing the patient data. We also thank the microbiology data-team of the Amsterdam UMC for providing the microbiological data.

Both Sophie Coenen and Jara R. de la Court have full access to the data used for this manuscript. The data that support the findings of this study are available from the corresponding author, upon reasonable request.

The authors have no conflicts of interest to declare that are relevant to the content of this article.

No financial support was used for this study.

All authors contributed to the study conception and design. Data collection was performed by Sophie Coenen, data analysis was performed by Jara R. de la Court. The expert panel All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 2, 2021. (7):442-A.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259020 doi: medRxiv preprint